



FOR IMMEDIATE RELEASE

September 12, 2007

**Aptus Endosystems Announces First Enrollment
in STAPLE-2 Pivotal Clinical Trial**

**Clinical Trial Designed to Demonstrate Safety & Effectiveness
of New Technology for Endovascular Aneurysm Repair**

(Sunnyvale, CA) - Aptus Endosystems, Inc. today announced that Michael G. Douglas, MD and John P. Henretta MD, of Carolina Vascular, a division of Asheville Radiology, performed the first procedure as part of the multicenter STAPLE-2 Clinical Trial to assess the safety and effectiveness of the Aptus™ Endovascular AAA Repair System. The Aptus™ Endograft and EndoStapling System, which together form a novel and promising new technology platform for the minimally invasive repair of abdominal aortic aneurysms (AAA), were successfully deployed in a procedure completed on September 11, 2007 at Mission Hospital, Asheville, NC.

The patient is the first of up to 135 patients slated for enrollment in the pivotal phase of Aptus Endosystems' clinical study, being conducted at up to 25 medical institutions in the United States. The company recently completed its STAPLE-1 Feasibility Study, successfully enrolling 21 patients at 5 US medical centers, and designed to demonstrate the safety and feasibility of the system.

Endovascular repair of aortic aneurysms has been approved in the United States since 1999. While widely accepted as a less invasive procedure with fewer complications, the long term durability of current endografts has been a subject of great debate. Shifting, or migration, of the endograft has been responsible for late failure in some cases and has limited the widespread applicability of this otherwise promising technique. Additionally, the size of the device is often too large for appropriate vessel access resulting in denial of patients for an endovascular approach to the repair.

The current endograft system, manufactured by Aptus Endosystems, Inc., is the first to be attached to the aorta with individual EndoStaples that reproduce the suture fixation used in open surgical repair of AAA. The capability to deliver these EndoStaples independent of endograft deployment, and at selected sites within the vessel, makes it possible to provide a much smaller delivery system for the endograft itself. It also secures the endograft in place in a manner that emulates the way grafts are secured in

open surgical repair that has proven long term results. "Secure fixation with the ability to place the device precisely where you want it ... it mimics open surgery" commented Dr. Douglas. "I left the case feeling that I provided my patient with a very good and durable result" added Dr. Henretta, site Principal Investigator for the Asheville group.

The STAPLE-2 Clinical Trial is lead by Dr. Ronald Fairman of the Hospital of the University of Pennsylvania and Dr. Manish Mehta of the Albany Medical Center as co-National Principal Investigators. "We are privileged to have two vascular surgeons with such extensive clinical experience in endovascular aneurysm repair leading this very important clinical study", noted Bob H. Katz, President of Aptus Endosystems.

AAA is 80-90% fatal if left untreated and is the 13th leading cause of death in the United States, responsible for more than 15,000 deaths each year, according to The Society for Vascular Surgery and Society of Interventional Radiology.

Aptus Endosystems is a privately held, emerging medical device company located in Sunnyvale, CA, that is engaged in the development of next generation minimally invasive endograft devices, delivery systems and fixation technology for the treatment of thoracic and abdominal aortic aneurysms. For more information, please visit www.apтусendosystems.com.

#####

Media Contact:

Bob H. Katz
President
Aptus Endosystems, Inc.
Tel. #408.530.9050 ext. 303
Email: bkatz@apтусendo.com